BHC(SH:600721)2023-04-25 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 75,710,434.22, representing an increase of 28.77% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was CNY 6,686,853.20, a significant increase of 387.32% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 6,225,735.69, reflecting a remarkable increase of 558.28% compared to the previous year[5] - The basic earnings per share for Q1 2023 was CNY 0.0177, up by 378.38% year-on-year[5] - The total revenue for Q1 2023 was ¥75,710,434.22, representing an increase of 28.7% compared to ¥58,796,482.88 in Q1 2022[18] - The net profit for Q1 2023 was ¥6,686,853.20, a significant increase from ¥1,378,890.58 in Q1 2022, marking a growth of 385.5%[19] - The basic earnings per share of ¥0.0177 for Q1 2023, compared to ¥0.0037 in Q1 2022, representing a growth of 378.4%[19] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 1,005,621,806.46, a slight increase of 0.43% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to ¥1,005,621,806.46, slightly up from ¥1,001,329,612.78 as of December 31, 2022[15] - The total liabilities decreased to ¥328,960,581.90 from ¥334,306,129.32, indicating a reduction of approximately 1.0%[16] - The equity attributable to shareholders increased to CNY 676,661,224.56, marking a growth of 1.44% compared to the end of the previous year[6] Cash Flow - The company reported a net cash flow from operating activities of CNY -11,349,578.00, indicating a decrease of 10.51% year-on-year[5] - In Q1 2023, the cash inflow from operating activities was CNY 66,346,463.62, an increase of 12.5% compared to CNY 59,101,524.63 in Q1 2022[21] - The net cash flow from operating activities was -CNY 11,349,578.00, showing an improvement from -CNY 12,682,485.50 in the same period last year[21] - The total cash and cash equivalents at the end of Q1 2023 were CNY 70,793,279.18, compared to CNY 49,289,567.66 at the end of Q1 2022, reflecting a year-over-year increase of 43.7%[22] - The company reported a total cash outflow from operating activities of CNY 77,696,041.62, up from CNY 71,784,010.13 in Q1 2022, indicating a 8.5% increase[21] Research and Development - Research and development expenses increased by 41.02% year-on-year, primarily due to increased investment in pharmaceutical research[9] - Research and development expenses for Q1 2023 were ¥6,139,950.63, up from ¥4,354,071.54 in Q1 2022, an increase of 40.9%[18] Investment Income - The company experienced a 170.93% increase in investment income, attributed to profits from its associate company[9] - The company received CNY 192,022.02 in investment income, up from CNY 97,648.93 in Q1 2022, marking a 96.5% increase[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,280[10]